Gastroesophageal Reflux Disease (GERD) Therapeutics%-%Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released a new report, “Gastroesophageal Reflux Disease (GERD) Therapeutics – Pipeline Assessment and Market Forecast to 2017”. The report is an essential source of information and analysis on the global GERD market. The report identifies the key trends shaping and driving the global GERD market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global GERD sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global Gastroesophageal Reflux Disease (GERD) market was worth $ 21.5 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 8.7% for the next eight years to reach $10.4 billion by 2017. The high projected rate of decline is primarily attributable to the patent expiries of all Proton Pump Inhibitors (PPIs) by the end of the forecast period. Increase in the treatment seeking population, the diagnosis population and long term anti-reflux maintenance therapy are expected to sustain the GERD market.
Scope
The scope of the report includes:
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global GERD market. Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global GERD market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What’s the next big thing in the global GERD market landscape? – Identify, understand and capitalize.
Summary
GlobalData, the industry analysis specialist, has released a new report, “Gastroesophageal Reflux Disease (GERD) Therapeutics – Pipeline Assessment and Market Forecast to 2017”. The report is an essential source of information and analysis on the global GERD market. The report identifies the key trends shaping and driving the global GERD market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global GERD sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global Gastroesophageal Reflux Disease (GERD) market was worth $ 21.5 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 8.7% for the next eight years to reach $10.4 billion by 2017. The high projected rate of decline is primarily attributable to the patent expiries of all Proton Pump Inhibitors (PPIs) by the end of the forecast period. Increase in the treatment seeking population, the diagnosis population and long term anti-reflux maintenance therapy are expected to sustain the GERD market.
Scope
The scope of the report includes:
- Annualized global GERD market revenues data from 2001 to 2009, forecast forward for 8 years to 2017.
- Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include H+/K+ ATPase Inhibitors, H2 antagonists, 5-HT4 receptor agonists and GABA-B receptor agonists.
- Analysis of the current and future market competition in the global GERD market. Key market players covered are AstraZeneca, XenoPort and Vecta.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with GERD
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 GASTROESOPHAGEAL REFLUX DISEASE (GERD) THERAPEUTICS MARKET – INTRODUCTION
2.1 GlobalData Pipeline Report Guidance
3 GERD THERAPEUTICS MARKET – MARKET CHARACTERIZATION
3.1 Overview
3.2 GERD Therapeutics Market Size
3.3 GERD Therapeutics Market Forecast and CAGR
3.4 Drivers and Barriers for the GERD Therapeutics Market
3.4.1 Drivers for the GERD Therapeutics Market
3.4.2 Barriers for the GERD Therapeutics Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway
4 GERD THERAPEUTICS MARKET – COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Portfolio for Major Marketed Products in the GERD Therapeutics Market
4.3.1 Nexium (esomeprazole)
4.3.2 Aciphex (Rabeprazole sodium)
4.3.3 Prevacid (lansoprazole)
4.3.4 Prilosec (omeprazole)
4.3.5 Protonix (pantoprazole sodium)
4.3.6 Tagamet (cimetidine)
4.3.7 Pepcid (famotidine)
4.3.8 Zantac (ranitidine hydrochloride)
4.3.9 Axid (nizatidine)
4.4 Key Takeaway
5 GERD THERAPEUTICS MARKET – PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytical Framework
5.3 GERD Therapeutics – Promising Drugs Under Clinical Development
5.4 Molecule Profiles for Promising Drugs Under Clinical Development
5.4.1 XP19986
5.4.2 AZD3355
5.4.3 Rozerem
5.4.4 Vecam
5.5 GERD Therapeutics Market – Pipeline Assessment by Mechanism of Action
5.6 GERD Therapeutics Market - Pipeline Assessment by Phase of Clinical Development
5.6.1 GERD Therapeutics – Phase III Clinical Pipeline
5.6.2 GERD Therapeutics – Phase II Clinical Pipeline
5.6.3 GERD Therapeutics – Phase I Clinical Pipeline
5.6.4 GERD Therapeutics – Pre-clinical Pipeline
5.6.5 GERD Therapeutics – Discovery Pipeline
5.7 Key Takeaway
6 GERD THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION
7 GERD THERAPEUTICS MARKET – KEY PLAYERS IN THE GERD THERAPEUTICS MARKET
7.1 XenoPort, Inc.
7.1.1 Company Overview
7.1.2 XP19986
7.2 AstraZeneca
7.2.1 Company Overview
7.2.2 AZD3355
7.3 Vecta Ltd. (Vecta)
7.3.1 Company Overview
7.3.2 Vecam
8 GERD THERAPEUTICS MARKET: APPENDIX
8.1 Market Definition
8.2 Abbreviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources 4
LIST OF TABLES
Table 1: GERD Therapeutics Market, Global, Revenues ($bn), 2001-2009
Table 2: GERD Therapeutics Market, Global, Revenue Forecasts ($ billion), 2009-2017
Table 3: Major Marketed Products Comparison in the GERD Therapeutics Market , 2010
Table 4: GERD Therapeutics Market, Global, Most Promising Molecules Under Clinical Development, February 2010
Table 5: GERD Therapeutics Market, Global, Phase III Clinical Pipeline, 2010
Table 6: GERD Therapeutics Market, Global, Phase II Clinical Pipeline, 2010
Table 7: GERD Therapeutics Market, Global, Phase I Clinical Pipeline, 2010
Table 8: GERD Therapeutics Market, Global, Pre-clinical Pipeline, 2010
Table 9: GERD Therapeutics Market, Global, Discovery Pipeline, 2010 32
LIST OF FIGURES
Figure 1: GERD Therapeutics Market, Global, Revenues ($bn), 2001-2009
Figure 2: GERD Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017
Figure 3: Opportunity and Unmet Need in the GERD Therapeutics Market
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in GERD Therapeutics Market, 2010
Figure 5: Technology Trends Analytic Framework of the GERD Therapeutics Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the GERD Therapeutics Pipeline – Description, 2010
Figure 7: GERD Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010
Figure 8: GERD Therapeutics Market, Global, Clinical Pipeline, 2010
Figure 9: Implications for Future Market Competition in the GERD Therapeutics Market, 2010
Figure 10: GERD Therapeutics Market, Global, Clinical Pipeline by Company, 2010
Figure 11: GlobalData Market Forecasting Model 43
COMPANIES MENTIONED
3M Health Care
A&D Medical
Abbott Laboratories
Agfa-Gevaert N.V.
Allscripts Healthcare Solutions Inc
Biosense Webster, Inc.
BIOTRONIK SE & Co. KG
Boston Scientific Corporation
C.R. Bard, Inc.
Carestream Health, Inc. / Kodak Health Group
Cerner Corporation
CompuGroup Medical AG.
Cordis Corporation
Covidien plc
Draegerwerk AG & Co. KGaA
Eclipsys Corporation
Edwards Lifesciences Corporation
ESAOTE S.p.A.
FUJIFILM Medical Systems USA, Inc.
Fujitsu Limited
Fukuda Denshi Co., Ltd.
GE Healthcare
Hartmann Group
Hitachi Medical Corporation
Hologic, Inc.
iSOFT Group plc
Konica Minolta Holdings, Inc.
McKesson Corporation
Medical Information Technology, Inc.
Medtronic, Inc.
Microlife Corporation
Mindray Medical International Limited
NEC Corporation
Nihon Kohden Corporation
OMRON HEALTHCARE Co., Ltd.
OSI Systems, Inc.
Samyang Corporation
Schiller AG
Shimadzu Corporation
Siemens Healthcare
SonoSite, Inc.
Sorin Group
St. Jude Medical, Inc.
Terumo Corporation
TietoEnator Corporation
Toshiba Medical Systems Corporation
TOSHIBA Medical Systems Corporation
Welch Allyn Inc.
1.1 List of Tables
1.2 List of Figures
2 GASTROESOPHAGEAL REFLUX DISEASE (GERD) THERAPEUTICS MARKET – INTRODUCTION
2.1 GlobalData Pipeline Report Guidance
3 GERD THERAPEUTICS MARKET – MARKET CHARACTERIZATION
3.1 Overview
3.2 GERD Therapeutics Market Size
3.3 GERD Therapeutics Market Forecast and CAGR
3.4 Drivers and Barriers for the GERD Therapeutics Market
3.4.1 Drivers for the GERD Therapeutics Market
3.4.2 Barriers for the GERD Therapeutics Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway
4 GERD THERAPEUTICS MARKET – COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Portfolio for Major Marketed Products in the GERD Therapeutics Market
4.3.1 Nexium (esomeprazole)
4.3.2 Aciphex (Rabeprazole sodium)
4.3.3 Prevacid (lansoprazole)
4.3.4 Prilosec (omeprazole)
4.3.5 Protonix (pantoprazole sodium)
4.3.6 Tagamet (cimetidine)
4.3.7 Pepcid (famotidine)
4.3.8 Zantac (ranitidine hydrochloride)
4.3.9 Axid (nizatidine)
4.4 Key Takeaway
5 GERD THERAPEUTICS MARKET – PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytical Framework
5.3 GERD Therapeutics – Promising Drugs Under Clinical Development
5.4 Molecule Profiles for Promising Drugs Under Clinical Development
5.4.1 XP19986
5.4.2 AZD3355
5.4.3 Rozerem
5.4.4 Vecam
5.5 GERD Therapeutics Market – Pipeline Assessment by Mechanism of Action
5.6 GERD Therapeutics Market - Pipeline Assessment by Phase of Clinical Development
5.6.1 GERD Therapeutics – Phase III Clinical Pipeline
5.6.2 GERD Therapeutics – Phase II Clinical Pipeline
5.6.3 GERD Therapeutics – Phase I Clinical Pipeline
5.6.4 GERD Therapeutics – Pre-clinical Pipeline
5.6.5 GERD Therapeutics – Discovery Pipeline
5.7 Key Takeaway
6 GERD THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION
7 GERD THERAPEUTICS MARKET – KEY PLAYERS IN THE GERD THERAPEUTICS MARKET
7.1 XenoPort, Inc.
7.1.1 Company Overview
7.1.2 XP19986
7.2 AstraZeneca
7.2.1 Company Overview
7.2.2 AZD3355
7.3 Vecta Ltd. (Vecta)
7.3.1 Company Overview
7.3.2 Vecam
8 GERD THERAPEUTICS MARKET: APPENDIX
8.1 Market Definition
8.2 Abbreviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources 4
LIST OF TABLES
Table 1: GERD Therapeutics Market, Global, Revenues ($bn), 2001-2009
Table 2: GERD Therapeutics Market, Global, Revenue Forecasts ($ billion), 2009-2017
Table 3: Major Marketed Products Comparison in the GERD Therapeutics Market , 2010
Table 4: GERD Therapeutics Market, Global, Most Promising Molecules Under Clinical Development, February 2010
Table 5: GERD Therapeutics Market, Global, Phase III Clinical Pipeline, 2010
Table 6: GERD Therapeutics Market, Global, Phase II Clinical Pipeline, 2010
Table 7: GERD Therapeutics Market, Global, Phase I Clinical Pipeline, 2010
Table 8: GERD Therapeutics Market, Global, Pre-clinical Pipeline, 2010
Table 9: GERD Therapeutics Market, Global, Discovery Pipeline, 2010 32
LIST OF FIGURES
Figure 1: GERD Therapeutics Market, Global, Revenues ($bn), 2001-2009
Figure 2: GERD Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017
Figure 3: Opportunity and Unmet Need in the GERD Therapeutics Market
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in GERD Therapeutics Market, 2010
Figure 5: Technology Trends Analytic Framework of the GERD Therapeutics Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the GERD Therapeutics Pipeline – Description, 2010
Figure 7: GERD Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010
Figure 8: GERD Therapeutics Market, Global, Clinical Pipeline, 2010
Figure 9: Implications for Future Market Competition in the GERD Therapeutics Market, 2010
Figure 10: GERD Therapeutics Market, Global, Clinical Pipeline by Company, 2010
Figure 11: GlobalData Market Forecasting Model 43
COMPANIES MENTIONED
3M Health Care
A&D Medical
Abbott Laboratories
Agfa-Gevaert N.V.
Allscripts Healthcare Solutions Inc
Biosense Webster, Inc.
BIOTRONIK SE & Co. KG
Boston Scientific Corporation
C.R. Bard, Inc.
Carestream Health, Inc. / Kodak Health Group
Cerner Corporation
CompuGroup Medical AG.
Cordis Corporation
Covidien plc
Draegerwerk AG & Co. KGaA
Eclipsys Corporation
Edwards Lifesciences Corporation
ESAOTE S.p.A.
FUJIFILM Medical Systems USA, Inc.
Fujitsu Limited
Fukuda Denshi Co., Ltd.
GE Healthcare
Hartmann Group
Hitachi Medical Corporation
Hologic, Inc.
iSOFT Group plc
Konica Minolta Holdings, Inc.
McKesson Corporation
Medical Information Technology, Inc.
Medtronic, Inc.
Microlife Corporation
Mindray Medical International Limited
NEC Corporation
Nihon Kohden Corporation
OMRON HEALTHCARE Co., Ltd.
OSI Systems, Inc.
Samyang Corporation
Schiller AG
Shimadzu Corporation
Siemens Healthcare
SonoSite, Inc.
Sorin Group
St. Jude Medical, Inc.
Terumo Corporation
TietoEnator Corporation
Toshiba Medical Systems Corporation
TOSHIBA Medical Systems Corporation
Welch Allyn Inc.